GT200900304A - "antagonistas ciclicos de peptido cxcr4" - Google Patents

"antagonistas ciclicos de peptido cxcr4"

Info

Publication number
GT200900304A
GT200900304A GT200900304A GT200900304A GT200900304A GT 200900304 A GT200900304 A GT 200900304A GT 200900304 A GT200900304 A GT 200900304A GT 200900304 A GT200900304 A GT 200900304A GT 200900304 A GT200900304 A GT 200900304A
Authority
GT
Guatemala
Prior art keywords
cxcr4
peptide antagonists
cycle peptide
cycle
novedous
Prior art date
Application number
GT200900304A
Other languages
English (en)
Spanish (es)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900304(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900304A publication Critical patent/GT200900304A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GT200900304A 2007-05-30 2009-11-26 "antagonistas ciclicos de peptido cxcr4" GT200900304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
GT200900304A true GT200900304A (es) 2011-11-09

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900304A GT200900304A (es) 2007-05-30 2009-11-26 "antagonistas ciclicos de peptido cxcr4"

Country Status (32)

Country Link
US (3) US7691813B2 (OSRAM)
EP (2) EP2160221B1 (OSRAM)
JP (1) JP5358564B2 (OSRAM)
KR (2) KR101319740B1 (OSRAM)
CN (1) CN101678213B (OSRAM)
AR (1) AR066648A1 (OSRAM)
AT (1) ATE516853T1 (OSRAM)
AU (1) AU2008260326B2 (OSRAM)
BR (1) BRPI0812134A2 (OSRAM)
CA (1) CA2688574C (OSRAM)
CL (1) CL2008001467A1 (OSRAM)
CO (1) CO6241137A2 (OSRAM)
CR (1) CR11105A (OSRAM)
CY (1) CY1111815T1 (OSRAM)
DK (1) DK2160221T3 (OSRAM)
DO (1) DOP2009000270A (OSRAM)
EA (1) EA017716B1 (OSRAM)
GT (1) GT200900304A (OSRAM)
HR (1) HRP20110551T1 (OSRAM)
IL (1) IL201685A (OSRAM)
JO (1) JO2776B1 (OSRAM)
MA (1) MA31666B1 (OSRAM)
MX (1) MX2009012952A (OSRAM)
MY (1) MY149432A (OSRAM)
NZ (1) NZ580849A (OSRAM)
PE (1) PE20090299A1 (OSRAM)
PL (1) PL2160221T3 (OSRAM)
PT (1) PT2160221E (OSRAM)
TN (1) TN2009000496A1 (OSRAM)
TW (1) TWI423987B (OSRAM)
WO (1) WO2008150689A1 (OSRAM)
ZA (1) ZA200908345B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
WO2012168336A1 (en) * 2011-06-07 2012-12-13 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
KR20200043970A (ko) * 2017-09-05 2020-04-28 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
WO2019126796A1 (en) * 2017-12-21 2019-06-27 Mainline Biosciences Llc Composition comprising a therapeutic agent and a cxcr4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US11639373B2 (en) 2018-09-12 2023-05-02 Technische Universität München Therapeutic and diagnostic agents for cancer
CA3108450A1 (en) 2018-09-12 2020-03-19 Technische Universitat Munchen Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
JP7541532B2 (ja) * 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
WO2022082312A1 (en) * 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
TW202235429A (zh) * 2020-12-25 2022-09-16 日商中外製藥股份有限公司 含ｎ－置換－胺基酸殘基之胜肽化合物的製備方法
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
CN119325480A (zh) * 2022-04-20 2025-01-17 省卫生服务机构 靶向cxcr4的化合物及其制备和使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
CA2643744A1 (en) * 2006-02-27 2007-08-30 Technische Universitaet Muenchen Cancer imaging and treatment

Also Published As

Publication number Publication date
KR20100003737A (ko) 2010-01-11
HRP20110551T1 (hr) 2011-09-30
CA2688574C (en) 2014-02-18
JP2010529957A (ja) 2010-09-02
PE20090299A1 (es) 2009-03-19
BRPI0812134A2 (pt) 2014-11-18
EA017716B1 (ru) 2013-02-28
KR101319740B1 (ko) 2013-10-17
AU2008260326A1 (en) 2008-12-11
EP2160221A1 (en) 2010-03-10
NZ580849A (en) 2012-03-30
MA31666B1 (fr) 2010-09-01
EP2377579A1 (en) 2011-10-19
JO2776B1 (en) 2014-03-15
WO2008150689A1 (en) 2008-12-11
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
AU2008260326B2 (en) 2011-07-21
EP2160221B1 (en) 2011-07-20
TN2009000496A1 (en) 2011-03-31
USRE42274E1 (en) 2011-04-05
TWI423987B (zh) 2014-01-21
CL2008001467A1 (es) 2008-12-05
IL201685A0 (en) 2010-05-31
JP5358564B2 (ja) 2013-12-04
CN101678213A (zh) 2010-03-24
MY149432A (en) 2013-08-30
CN101678213B (zh) 2013-11-06
CR11105A (es) 2010-04-12
AR066648A1 (es) 2009-09-02
HK1141474A1 (en) 2010-11-12
KR101169846B1 (ko) 2012-08-01
PL2160221T3 (pl) 2011-12-30
CY1111815T1 (el) 2015-10-07
DK2160221T3 (da) 2011-09-19
US20100130409A1 (en) 2010-05-27
CO6241137A2 (es) 2011-01-20
DOP2009000270A (es) 2010-01-15
IL201685A (en) 2015-04-30
EA200971129A1 (ru) 2010-04-30
US7691813B2 (en) 2010-04-06
PT2160221E (pt) 2011-09-12
ATE516853T1 (de) 2011-08-15
TW200902556A (en) 2009-01-16
US20080300177A1 (en) 2008-12-04
MX2009012952A (es) 2009-12-11
CA2688574A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
GT200900304A (es) "antagonistas ciclicos de peptido cxcr4"
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
DE602007012443D1 (de) Zyklische angiotensinanaloga
ECSP11011163A (es) Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC
BRPI1014508A2 (pt) análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
CR20110509A (es) Composicion farmaceutica
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
MA32534B1 (fr) Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CL2013003484A1 (es) Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.
CL2016001405A1 (es) A peptide mixture
MX354125B (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
EA201001722A1 (ru) Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
MX347229B (es) Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
PE20200894A1 (es) Polipeptidos variantes del factor de crecimiento tipo insulina 1
EP2283352A4 (en) Acetaminophen TEST PROCEDURE
CL2007003688A1 (es) Compuestos derivados de 2-amino-1-fenil-etanol, antagonistas de los receptores de calcio; metodo de sintesis; compuesto intermediario; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como osteoartritis, artritis reumatoides, e
CL2010001471A1 (es) Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades..